CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
Public ClinicalTrials.gov record NCT07168486. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ia Study of Tri-specific CAR19.20.22 Chimeric Antigen Receptor (CAR) T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
Study identification
- NCT ID
- NCT07168486
- Recruitment status
- Enrolling by invitation
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Enrollment
- 15 participants
Conditions and interventions
Conditions
Interventions
- CD19.20.22 CAR T cells Biological
- Fludarabine and Cyclophosphamide Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 27, 2024
- Primary completion
- Jun 30, 2027
- Completion
- Jun 30, 2028
- Last update posted
- Sep 10, 2025
2024 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Maryland, Baltimore | Baltimore | Maryland | 21201 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07168486, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 10, 2025 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07168486 live on ClinicalTrials.gov.